| 0.3439 0.065 (23.3%) | 04-18 13:36 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.47 |
1-year : | 0.56 |
| Resists | First : | 0.4 |
Second : | 0.48 |
| Pivot price | 0.34 |
|||
| Supports | First : | 0.26 |
Second : | 0.22 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.35 |
| MA(100) : | 0.53 |
MA(250) : | 1.32 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.6 |
D(3) : | 21.8 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 4.21 | Low : | 0.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BPTS ] has closed above bottom band by 7.1%. Bollinger Bands are 31.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.32 - 0.32 | 0.32 - 0.32 |
| Low: | 0.26 - 0.26 | 0.26 - 0.27 |
| Close: | 0.29 - 0.29 | 0.29 - 0.29 |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Thu, 18 Apr 2024
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity - Yahoo Canada Finance
Tue, 09 Apr 2024
Biotech Catches Major Premarket Bid Following Financial Results - The Globe and Mail
Tue, 09 Apr 2024
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket - Markets Insider
Tue, 09 Apr 2024
Why Is Biophytis Stock Trading Higher Today? - Biophytis (NASDAQ:BPTS) - Benzinga
Tue, 09 Apr 2024
Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up - Yahoo Finance
Mon, 08 Apr 2024
Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 756 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 30 (K) |
| EPS | -3.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|